Loading
BH-30643 is an experimental small molecule from BlossomHill Therapeutics, in phase 1 trials for EGFR-mutant non-small cell lung cancer and HER2-mutant non-small cell lung cancer.
BH-30643 (OMNI-EGFR inhibitor) is a small molecule (oral, non-covalent, macrocyclic) from BlossomHill Therapeutics. An orally bioavailable, non-covalent, macrocyclic, brain-active, mutant-selective EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors, with selectivity over wild-type EGFR. Its furthest stage is phase 1, for EGFR-mutant non-small cell lung cancer and HER2-mutant non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Company pipeline shows Phase 1; the SOLARA registry entry is phase 1/2, recruiting. Whether it works in people has not been established unless a trial below reports it.
An orally bioavailable, non-covalent, macrocyclic, brain-active, mutant-selective EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors, with selectivity over wild-type EGFR. Connects to EGFR.
1.BH-30643 slips into a pocket on EGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BH-30643" OR ABSTRACT:"BH-30643" OR TITLE:"OMNI-EGFR inhibitor" OR ABSTRACT:"OMNI-EGFR inhibitor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BH-30643, not a curated reading list.
Shares HER2-mutant non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares BlossomHill Therapeutics and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/